1845PSafety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trialsMorten Mau-Sørensen, M van Bussel, M Kuipers,Dorte Nielsen,Henk M.W. Verheul,Philippe Aftimos,M.J.A. de Jonge,B. Van Triest, J Falkenius,Jürgen Debus,E.G.C. Troost,Michael Samuels,Barbara Sarholz,Volker Budach,Sanjay Goel,Giuseppe Locatelli,Poul F. GeertsenANNALS OF ONCOLOGY（2018）引用 16|浏览53暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
